Laboratory of Metabolomics and Molecular Imaging, BIONAND, Centro Andaluz de Nanomedicina y Biotecnología (Junta de Andalucía, Universidad de Málaga) Malaga, Spain.
Front Chem. 2014 Dec 18;2:112. doi: 10.3389/fchem.2014.00112. eCollection 2014.
Medical imaging technologies have undergone explosive growth over the past few decades and now play a central role in clinical oncology. But the truly transformative power of imaging in the clinical management of cancer patients lies ahead. Today, imaging is at a crossroads, with molecularly targeted imaging agents expected to broadly expand the capabilities of conventional anatomical imaging methods. Molecular imaging will allow clinicians to not only see where a tumor is located in the body, but also to visualize the expression and activity of specific molecules (e.g., proteases and protein kinases) and biological processes (e.g., apoptosis, angiogenesis, and metastasis) that influence tumor behavior and/or response to therapy. Breast cancer, the most common cancer among women and a research area where our group is actively involved, is a very heterogeneous disease with diverse patterns of development and response to treatment. Hence, molecular imaging is expected to have a major impact on this type of cancer, leading to important improvements in diagnosis, individualized treatment, and drug development, as well as our understanding of how breast cancer arises.
在过去几十年中,医学成像技术经历了爆炸式的增长,现在在临床肿瘤学中发挥着核心作用。但成像在癌症患者临床管理中的真正变革力量还在前面。今天,成像处于十字路口,预计分子靶向成像剂将广泛扩展传统解剖成像方法的功能。分子成像将使临床医生不仅能够看到肿瘤在体内的位置,还能够可视化特定分子(例如蛋白酶和蛋白激酶)和生物过程(例如细胞凋亡、血管生成和转移)的表达和活性,这些分子和生物过程影响肿瘤的行为和/或对治疗的反应。乳腺癌是女性中最常见的癌症,也是我们小组积极参与的研究领域,它是一种具有不同发展和治疗反应模式的高度异质性疾病。因此,分子成像有望对这种癌症产生重大影响,从而在诊断、个体化治疗和药物开发方面以及在我们对乳腺癌发生的理解方面取得重要进展。